Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>As per the Q1 2024 Cooper Companies earnings, the company reported an outstanding start to the fiscal year with record quarterly revenues of $932 million.</li><li>CooperVision rolled in solid growth worldwide, while CooperSurgical recorded its 13th consecutive quarter of double-digit organic growth.</li><li>The firm's earnings were equally strong, with capacity expansion progressing well and demand remaining healthy globally.</li></ul>

As per the Q1 2024 Cooper Companies earnings, the company reported an outstanding start to the fiscal year with record quarterly revenues of $932 million.CooperVision rolled in solid growth worldwide, while CooperSurgical recorded its 13th consecutive quarter of double-digit organic growth.The firm's earnings were equally strong, with capacity expansion progressing well and demand remaining healthy globally.

The Cooper Companies Inc.: Huge Potential Of Myopia Management Market As A Growth Catalyst! - Key Drivers

<ul><li>The Cooper Companies delivered a mixed result in Q4, with revenues above market expectations, but it failed to surpass the analyst consensus in terms of earnings.</li><li>CooperVision's outstanding performance stands out, achieving an impressive 11th consecutive quarter of double-digit organic growth.</li><li>MiSight's impressive 41% revenue growth in myopia management, driven by positive trends in the Americas and EMEA, solidifies Cooper's position in proactive myopia control.</li></ul>

The Cooper Companies delivered a mixed result in Q4, with revenues above market expectations, but it failed to surpass the analyst consensus in terms of earnings.CooperVision's outstanding performance stands out, achieving an impressive 11th consecutive quarter of double-digit organic growth.MiSight's impressive 41% revenue growth in myopia management, driven by positive trends in the Americas and EMEA, solidifies Cooper's position in proactive myopia control.

The Cooper Companies Inc.: Enhancement Of CooperSurgical's Medical Device Portfolio! - Major Drivers

<ul><li>The Cooper Companies delivered a positive result and managed an all-around beat in the last quarter.</li><li>The company surpassed revenue estimates, generating significant quarterly revenues of $930 million, driven by strong sustained organic growth.</li><li>CooperVision reported $630 million in revenue, up 13% organically, while CooperSurgical reported $300 million in revenue, up 9% organically.</li></ul>

The Cooper Companies delivered a positive result and managed an all-around beat in the last quarter.The company surpassed revenue estimates, generating significant quarterly revenues of $930 million, driven by strong sustained organic growth.CooperVision reported $630 million in revenue, up 13% organically, while CooperSurgical reported $300 million in revenue, up 9% organically.

The Cooper Companies: The Powerful Future of Fertility Business and How They're Leading! - Major Drivers

Equity Capital Markets

<ul><li>Cooper delivered a solid result and managed an all-around beat in the last quarter.</li><li>CooperSurgical also reported high revenues and achieved ten consecutive quarters of double-digit organic revenue growth, led by their fertility business.</li><li>In addition to the strong financial performance, CooperVision's new product launches, expanded product ranges, and market-leading flexibility contributed to the positive results.</li></ul>

Cooper delivered a solid result and managed an all-around beat in the last quarter.CooperSurgical also reported high revenues and achieved ten consecutive quarters of double-digit organic revenue growth, led by their fertility business.In addition to the strong financial performance, CooperVision's new product launches, expanded product ranges, and market-leading flexibility contributed to the positive results.

The Cooper Companies Inc.: Is It The Future Of Vision Correction? – Key Drivers

<ul><li>Cooper Companies had impressive Q3 results for both its CooperVision and CooperSurgical divisions and managed an all-around beat.</li><li>CooperVision experienced strong and diversified growth in all product categories, with its Daily Silicone hydrogel portfolio and myopia management products leading the way.</li><li>The company's growth in the myopia management market has been strong, with revenues up 42%, and it remains a market leader with its FDA-approved MiSight product.</li></ul>

Cooper Companies had impressive Q3 results for both its CooperVision and CooperSurgical divisions and managed an all-around beat.CooperVision experienced strong and diversified growth in all product categories, with its Daily Silicone hydrogel portfolio and myopia management products leading the way.The company's growth in the myopia management market has been strong, with revenues up 42%, and it remains a market leader with its FDA-approved MiSight product.

Cooper Companies Inc: Reaping The Fruits Of Myopia Management – Key Drivers

United States

The Cooper Companies, Inc. through its subsidiaries, develops, manufactures, and markets specialty healthcare products. The Company's products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cooper Cos / (COO UN)

The Cooper Companies Inc.: Huge Potential Of Myopia Management Market As A Growth Catalyst! - Key Drivers

As per the Q1 2024 Cooper Companies earnings, the company reported an outstanding start to the fiscal year with record quarterly revenues of $932...

Baptista Research

The Cooper Companies Inc.: Enhancement Of CooperSurgical's Medical Device Portfolio! - Major Drivers

The Cooper Companies delivered a mixed result in Q4, with revenues above market expectations, but it failed to surpass the analyst consensus in...

Baptista Research

The Cooper Companies: The Powerful Future of Fertility Business and How They're Leading! - Major Drivers

The Cooper Companies delivered a positive result and managed an all-around beat in the last quarter. The company surpassed revenue estimates,...

Baptista Research

The Cooper Companies Inc.: Is It The Future Of Vision Correction? – Key Drivers

Cooper delivered a solid result and managed an all-around beat in the last quarter. CooperSurgical also reported high revenues and achieved ten...

Baptista Research

Cooper Companies Inc: Reaping The Fruits Of Myopia Management – Key Drivers

Cooper Companies had impressive Q3 results for both its CooperVision and CooperSurgical divisions and managed an all-around beat. CooperVision...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)